Comparative bioavailability of Silipide, a new flavanolignan complex, in rats

Eur J Drug Metab Pharmacokinet. Jan-Mar 1992;17(1):39-44. doi: 10.1007/BF03189986.

Abstract

The comparative pharmacokinetics of Silipide (IdB 1016, a silybin-phosphatidylcholine complex) and silybin were investigated by measuring unconjugated and total plasma silybin levels as well as total biliary and urinary silybin excretion in rats following administration of a single oral dose (200 mg/kg as silybin). Mean peak levels of unconjugated and total silybin after IdB 1016 were 8.17 and 74.23 micrograms/ml respectively. Mean AUC (0-6 h) values were 9.78 and 232.15 h.micrograms.ml-1 indicating that about 94% of the plasma silybin is present in a conjugated form. After administration of silybin, plasma levels of both unconjugated and total compound were under the analytical detection limit. Cumulative biliary (0-24 h) and urinary (0-72 h) excretion values after administration of IdB 1016 accounted for 3.73% and 3.26% of the administered dose, respectively. After silybin administration, the biliary and urinary excretion accounted for only 0.001% and 0.032% of the dose respectively. Our results indicate a superior bioavailability of silybin administered orally as IdB 1016. This was due mainly to an impressive increase in gastrointestinal absorption.

Publication types

  • Comparative Study

MeSH terms

  • Animals
  • Bile / chemistry
  • Biological Availability
  • Chromatography, High Pressure Liquid
  • Male
  • Phosphatidylcholines / pharmacokinetics*
  • Rats
  • Rats, Inbred Strains
  • Silymarin / blood
  • Silymarin / pharmacokinetics*
  • Silymarin / urine

Substances

  • Phosphatidylcholines
  • Silymarin
  • IdB 1016